A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

• Egile Nagusiak: Ying Jin (Egilea), Zhifei Xu (Egilea), Hao Yan (Egilea), Qiaojun He (Egilea), Xiaochun Yang (Egilea), Peihua Luo (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2020-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Numerous protein kinases encoded in the genome have become attractive targets for the treatment of different types of cancer. As of January 2020, a total of 52 small-molecule kinase inhibitors (SMKIs) have been approved by the FDA. With the numerous clinical trials and a heavy focus on drug safety,...